# Clearmind Biomedical

- Location (FDA's records): Taipei, TW
- FDA decisions: 3 (2020–2023): 3 510(k) clearances
- Product codes: GWG (3)
- Predicates its devices cite: 5 (1 its own); citations of its devices by later devices: 1 (1 its own)
- Recalls linked to its devices: 0 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Firms whose devices it cites most
- Penumbra, Inc.: 2 (https://510kreport.com/company/penumbra)
- Aesculap, Inc.: 1 (https://510kreport.com/company/aesculap)
- Rebound Therapeutics: 1 (https://510kreport.com/company/rebound-therapeutics)

## Its most-cited devices
- K201308: Axonpen, Axonmonitor, Axonbox, Tablet (2020), cited by 1

## Recent decisions
- K230125: Neuroblade System (Oct 13, 2023)
- K210251: ClearPath Disposable Introducer (Apr 2, 2021)
- K201308: Axonpen, Axonmonitor, Axonbox, Tablet (Nov 27, 2020)

Source page: https://510kreport.com/company/clearmind-biomedical